帕博利珠单抗治疗罕见及超罕见肉瘤(AcSé帕博利珠单抗研究):非随机、开放标签、2期篮式试验亚组分析
AcSé帕博利珠单抗研究为持续进行的2期篮式多瘤种研究,在24家法国医院纳入98例罕见及超罕见肉瘤患者(97例接受治疗并分析),每21天静脉给予帕博利珠单抗200 mg、最长24个月。第12周客观缓解率为6.2%(95%CI 2.3-13.0),无完全缓解、6例部分缓解;常见3-4级不良事件为贫血(8/97,8%)、丙氨酸氨基转移酶及天冬氨酸氨基转移酶升高(6/97,6%)和呼吸困难(5/97,5%)。作者认为数据提示帕博利珠单抗在部分罕见及超罕见肉瘤组织学亚型中具有活性和可管理的毒性。
要点
- 第12周客观缓解率为6.2%(95%CI 2.3-13.0),97例中无完全缓解、6例部分缓解。
- 97例中最常见3-4级不良事件为贫血8例(8%)、转氨酶升高6例(6%)、呼吸困难5例(5%)。
- 37例报告86起严重不良事件,5例因不良事件死亡、均判定与治疗无关。
核心结论
- 在部分罕见及超罕见肉瘤组织学亚型中,帕博利珠单抗显示出活性且毒性可管理。
- 作者认为支持PD-1/PD-L1通路作为选定组织学亚型的潜在治疗靶点。
- 完成该篮式研究将提供关于帕博利珠单抗在已识别罕见癌症类型中活性和毒性的进一步证据。
研究设计与样本
- AcSé帕博利珠单抗为持续进行的2期、篮式、多瘤种研究,评估帕博利珠单抗单药治疗罕见癌症。
- 本报告为选定罕见肉瘤组织学亚型(年发病率低于每100万人1例)患者,在24家法国医院招募。
- 关键纳入标准为年龄15岁及以上、ECOG体能状态0-1、晚期疾病且未经治疗或对治疗耐药。
- 给药方案为帕博利珠单抗200 mg静脉给药,每21天周期第1天,最长24个月。
- 主要终点为第12周客观缓解率,采用实体瘤疗效评价标准1.1版、由当地研究者评估;主要终点与安全性在意向治疗人群中分析。
主要发现
- 2017年9月4日至2020年12月29日入组98例,其中97例接受治疗并纳入分析;中位年龄51岁(IQR 35-65),53例(55%)男性、44例(45%)女性。
- 组织学亚型:脊索瘤34例(35%)、腺泡状软组织肉瘤14例(14%)、SMARCA4缺陷型肉瘤或恶性横纹肌样瘤12例(12%)、促纤维增生性小圆细胞肿瘤8例(8%)、上皮样肉瘤6例(6%)、树突细胞肉瘤4例(4%)、透明细胞肉瘤、孤立性纤维性肿瘤、黏液样脂肪肉瘤各3例(3%),其他超罕见亚型10例(10%)。
- 截至数据截止日(2022年4月11日),中位随访13.1个月(范围0.1-52.8;IQR 4.3-19.7)。
- 第12周客观缓解率为6.2%(95%CI 2.3-13.0),97例中无完全缓解、6例部分缓解。
- 97例中最常见3-4级不良事件为贫血8例(8%)、丙氨酸氨基转移酶和天冬氨酸氨基转移酶升高6例(6%)、呼吸困难5例(5%);37例报告86起严重不良事件;5例因不良事件死亡,均判定与治疗无关(2例疾病进展、2例癌症、1例原因不明)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sarcoma is a heterogeneous group of diseases with few treatment options. Immunotherapy has shown little activity in studies including unselected sarcomas, but immune checkpoint blockers have shown activity in specific histotypes. We evaluated the activity of pembrolizumab in rare and ultra-rare sarcomas. METHODS: AcSé Pembrolizumab is an ongoing phase 2, basket, multitumour study investigating the activity of pembrolizumab monotherapy in rare cancers. Here, we report the results obtained in patients with selected histotypes of rare sarcomas (incidence of less than one case per 1 000 000 people per year) recruited at 24 French hospitals. Key inclusion criteria were age 15 years or older, Eastern Cooperative Oncology Group performance status of 0-1, and advanced disease that was untreated and resistant to treatment. Patients were given pembrolizumab 200 mg intravenously on day 1 of every 21-day cycle for a maximum of 24 months. The primary endpoint was objective response rate at week 12 using Response Evaluation Criteria in Solid Tumours version 1.1, assessed by local investigators. The primary endpoint and safety were analysed in the intention-to-treat population. The AcSé Pembrolizumab study is registered with ClinicalTrials.gov, NCT03012620. FINDINGS: Between Sept 4, 2017, and Dec 29, 2020, 98 patients were enrolled, of whom 97 received treatment and were included in analyses (median age 51 years [IQR 35-65]; 53 [55%] were male; 44 [45%] were female; no data were collected on race or ethnicity). 34 (35%) patients had chordomas, 14 (14%) had alveolar soft part sarcomas, 12 (12%) had SMARCA4-deficient sarcomas or malignant rhabdoid tumours, eight (8%) had desmoplastic small round cell tumours, six (6%) had epithelioid sarcomas, four (4%) had dendritic cell sarcomas, three (3%) each had clear cell sarcomas, solitary fibrous tumours, and myxoid liposarcomas, and ten (10%) had other ultra-rare histotypes. As of data cutoff (April 11, 2022), median follow-up was 13·1 months (range 0·1-52·8; IQR 4·3-19·7). At week 12, objective response rate was 6·2% (95% CI 2·3-13·0), with no complete responses and six partial responses in the 97 patients. The most common grade 3-4 adverse events were anaemia (eight [8%] of 97), alanine aminotransferase and aspartate aminotransferase increase (six [6%]), and dyspnoea (five [5%]). 86 serious adverse events were reported in 37 patients. Five deaths due to adverse events were reported, none of which were determined to be related to treatment (two due to disease progression, two due to cancer, and one due to unknown cause). INTERPRETATION: Our data show the activity and manageable toxicity of pembrolizumab in some rare and ultra-rare sarcoma histotypes, and support the PD-1/PD-L1 pathway as a potential therapeutic target in selected histotypes. The completion of the basket study will provide further evidence regarding the activity and toxicity of pembrolizumab in identified rare types of cancer. FUNDING: The Ligue contre le cancer, INCa, MSD. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
引用
- Blay JY, Chevret S, Le Cesne A, et al. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. Lancet Oncol. 2023. PMID: 37429302. doi:10.1016/S1470-2045(23)00282-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。